Your browser doesn't support javascript.
loading
Effect of cilobradine in cats with a first episode of congestive heart failure due to primary cardiomyopathy.
Riesen, S C; Bomassi, E; Bracke, A; Den Hertog, E; Dukes-McEwan, J; Eichhorn, G; French, A; Höpfner, R; Kirsch, A; Little, C J L; Loureiro, J; Menaut, P; Papadopulo, I; Rønn-Landbo, M; Schiller, S; Serres, F; Smith, S; Veloso, G F; Wess, G; Zoller, C; Albrecht, B.
Afiliación
  • Riesen SC; Corresponding Address Kardiovet GmbH, Eystrasse 74, Kirchberg, Switzerland; Department for Companion Animals and Horses, University of Veterinary Medicine, Veterinärplatz, Vienna, Austria. Electronic address: s.riesen@kardiovet.ch.
  • Bomassi E; Centre Hospitalier Vétérinaire des Cordeliers, 35 Avenue Du Maréchal Joffre, 77100 Meaux, France.
  • Bracke A; Tierärztliche Gemeinschaftspraxis, An Den Wurthen 26, 17489 Greifswald, Germany.
  • Den Hertog E; Medisch Centrum voor Dieren, Isolatorweg 45, 1014 AS Amsterdam, the Netherlands.
  • Dukes-McEwan J; Small Animal Teaching Hospital, Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston, Cheshire CH64 7TE, UK.
  • Eichhorn G; Tierklinik Bockenheim, Juliusstrasse 12, 60487 Frankfurt, Germany.
  • French A; Ross University School of Veterinary Medicine, Basseterre, St. Kitts West Indies, St. Kitts and Nevis.
  • Höpfner R; Kleintierspezialisten Dres. Schmerbach & Höpfner, Wittestr. 30, 13509 Berlin, Germany.
  • Kirsch A; Tiergesundheitszentrum Obere Hard, Überweisungspraxis für Innere Medizin und Kardiologie, Oberer Hardweg 16, 75181 Pforzheim, Germany.
  • Little CJL; Barton Veterinary Hospital and Surgery, CVS (UK) Ltd, 34 New Dover Road, Canterbury, Kent CT1 3BH, UK.
  • Loureiro J; North Downs Specialist Referrals, The Friesian Building 3 & 4, The Brewerstreet Dairy Business Park, Brewer Street, Bletchingley, Surrey RH1 4QP, UK.
  • Menaut P; Clinique Vétérinaire Aquivet, 19 Avenue de La Forêt, Parc d'activités Mermoz, 33320 Eysines, France.
  • Papadopulo I; Clinique Vétérinaire Armonia, Rue Serge Mauroit, 38090 Villefontaine, France.
  • Rønn-Landbo M; Aalborg Dyrehospital, Fredrikstadvej 10, 9200 Aalborg SV, Denmark.
  • Schiller S; Kleintierzentrum Walluf, Am Klingenweg 21, 65396 Walluf, Germany; Tierärztliche Klinik Oberhaching, Bajuwarenring 10, 82041 Oberhaching, Germany.
  • Serres F; Oncovet Clinique Vétérinaire de Référés, Avenue Paul Langevin, 59650 Villeneuve d'Ascq, France.
  • Smith S; Ivy Court, Willington Rd, Etwall, Derbyshire DE65 6JG, UK.
  • Veloso GF; Anderson Moores Veterinary Specialists, The Granary, Bunstead Barns, Poles Lane, Hursley, Winchester, Hampshire SO21 2LL, UK.
  • Wess G; Clinic of Small Animal Medicine, Ludwig-Maximilians University, Veterinärstrasse 13, 80539 Munich, Germany.
  • Zoller C; Clinique Vétérinaire Foch, 38 Avenue du Maréchal Foch, 34500 Beziers, France.
  • Albrecht B; Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173, 55216 Ingelheim Am Rhein, Germany.
J Vet Cardiol ; 41: 179-193, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35366640
INTRODUCTION: Heart rate (HR) is often elevated in cats with cardiomyopathies (CMPs). Pharmacologic modulation of HR may reduce cardiac morbidity and mortality. OBJECTIVES: To investigate the effects of cilobradine vs. placebo, regarding time to cardiac mortality or morbidity in cats with first episode of congestive heart failure (CHF) due to primary CMP. ANIMALS: Three hundred and sixty-seven client-owned cats with primary CMP that had presented with a first episode of CHF at 50 centers in Europe. Per-protocol population comprised 193 cats (n = 89 cilobradine, n = 104 placebo). An interim analysis for futility was planned. METHODS: Prospective, randomized, placebo-controlled, double-blinded, multicenter clinical trial. Primary outcome variable was the time to a composite of cardiac mortality or cardiac morbidity. RESULTS: Median time to primary outcome was 84 days (95% confidence interval [CI]: 63-219 days) in the cilobradine group (CG) and 203 days in the placebo group (95% CI: 145-377 days) with observed hazard ratio of 1.44, indicating a higher hazard for the CG (P = 0.057). Mean HR was 28 beats per minute (bpm) lower at Day 7 (P < 0.0001) and remained 29 bpm lower at Day 360 (P = 0.026) in the CG than that in the placebo group. Although the number of adverse events did not differ, there were more serious adverse events in the CG. CONCLUSIONS: Heart rate reduction by cilobradine in cats with a first episode of CHF due to primary CMP did not reduce cardiac mortality and morbidity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de los Gatos / Insuficiencia Cardíaca / Cardiomiopatías Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Vet Cardiol Asunto de la revista: CARDIOLOGIA / MEDICINA VETERINARIA Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades de los Gatos / Insuficiencia Cardíaca / Cardiomiopatías Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: J Vet Cardiol Asunto de la revista: CARDIOLOGIA / MEDICINA VETERINARIA Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos